Moomoo AI 已提取核心信息
Avenue Therapeutics, a pharmaceutical company, has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review its Registration Statement on Form S-3, which was filed on January 24, 2024. The SEC's communication, dated January 29, 2024, was addressed to Alix MacLean, CEO of Avenue Therapeutics, and highlighted that the responsibility for the accuracy and adequacy of disclosures lies with the company and its management. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Avenue Therapeutics has been directed to contact Tamika Sheppard at the SEC with any further questions.
Avenue Therapeutics, a pharmaceutical company, has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review its Registration Statement on Form S-3, which was filed on January 24, 2024. The SEC's communication, dated January 29, 2024, was addressed to Alix MacLean, CEO of Avenue Therapeutics, and highlighted that the responsibility for the accuracy and adequacy of disclosures lies with the company and its management. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Avenue Therapeutics has been directed to contact Tamika Sheppard at the SEC with any further questions.
生命科学公司财务部已告知制药公司Avenue Therapeutics，美国证券交易委员会（SEC）不会审查其于2024年1月24日提交的S-3表格注册声明。美国证券交易委员会于2024年1月29日致函Avenue Therapeutics首席执行官阿利克斯·麦克莱恩，并强调披露准确性和充分性的责任在于公司及其管理层。美国证券交易委员会还引用了第460和461条，这两条规则与加快注册程序的请求有关。如有任何其他问题，Avenue Therapeutics已被指示联系美国证券交易委员会的塔米卡·谢泼德。
生命科学公司财务部已告知制药公司Avenue Therapeutics，美国证券交易委员会（SEC）不会审查其于2024年1月24日提交的S-3表格注册声明。美国证券交易委员会于2024年1月29日致函Avenue Therapeutics首席执行官阿利克斯·麦克莱恩，并强调披露准确性和充分性的责任在于公司及其管理层。美国证券交易委员会还引用了第460和461条，这两条规则与加快注册程序的请求有关。如有任何其他问题，Avenue Therapeutics已被指示联系美国证券交易委员会的塔米卡·谢泼德。
有用
没用